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ABSTRACT

An inactivated viral vaccine for protecting horses

against disease caused by equine rhinopneumonitis virus
is prepared by propagating an equine rhinopneumonitis
virus in a susceptible, cloned, diploid equine cell line,
harvesting the resulting virus in a serum-free medium,

inactivating the virus and neutralizing the inactivating
agent, concentrating the virus, and adding an immuno
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any abnormal chromosome markers and containing the
normal modal chromosome number for Equus caballus

INACTIVATED EQUINE RHINOPNEUMONITIS
VIRUS VACCINE AND USE THEREOF

(64),

(B) Preparing from this cell culture, single cell cloned

This invention relates to the development of a pre
ventive immunization method for protecting pregnant -

mares against the abortigenic effect of equine rhinop
neumonitis virus (equine herpesvirus I) infection and of
protecting young horses against disease caused by their

diploid cell lines which by karyotypic analysis reveal a
stable emploidy and showing, by virus culture, electron
microscopy, bacteriological culture and uridine-uracil
ratio, that such cell lines are free of adventitious viruses,
bacterial or mycoplasma,

infection by the same virus and to the process of prepa 10

ration of the potent vaccine.

(C) Determining by inoculation of horses and prepa
ration of antiserums in rabbits against the cell culture
that the cell culture contains no equine red blood cell

The equine rhinopneumonitis virus (ERV), a typical
member of the Herpesvirus group, infects the respira

antigens,

tory mucosa and subjacent or associated lymphoreticu
lar organs leading to development of a cell-associated F. 5
viremic state which may lead to abortigenic infection of
the fetus in pregnant mares. The economic losses conse
quent to disease produced by this infection in young
horses result from inability or impaired ability to per

form in competition. The economic losses resulting 20
from infection of pregnant mares are due to abortion.
The disease occurs in enzootic form but may occur in
epizootic form resulting in fetal or neonatal loss of

-

(D) Inoculating such cell lines with a multiplicity of
infections shown to produce maximum infectious virus
particle yields of a stable macroplaque strain of an anti

genically typical equine rhinopneumonitis virus and
causing the virus to be released into a serum-free me

dium, and

(E) Harvesting such serum-free virus containing ma
terial from infected cell culture, removing cell culture

debris by centrifugation, chemically inactivating infec
tivity of the virus with such chemicals as formalin,

Hitherto, it has not been possible to prevent such loss

beta-propiolactone or acetylethylenimine, neutralizing
any residual chemical, concentrating the virus by ultra
?ltration, adding a stabilizing agent, adding a preserva

without risk of vaccine induced abortic infection in
which living virus vaccines are administered either

tive, ascertaining that no residual infectious virus is
present and mixing the virus with an oil based immuno

greater than 50 percent of expected foal crop produc
tion in individual bands of mares.

intranasally

or

parenterally.

25

Infectious

(living

logic adjuvant. Said virus before addition of adjuvant
must meet the following criteria for inactivation and
integrity of structure:
(a) Virus is pelleted from a 100 ml sample of the

attenuated) vaccines may not be used except in early or
mid-gestation, these periods being the least critical dur
ing which protection is required.
1
It is known that certain properly constituted, chemi
cally inactivated, non-infectious viral vaccines will pro

completely mixed but unconcentrated inactivated virus
base pool by centrifugation at 25,000 rpm for 1 hour.

tect mammals against disease caused by speci?c viruses.

The pellet is resuspended in a few ml of serum-free
balanced salt solution and two con?uent monolayers of
susceptible cell cultures are inoculated, each with half
of the concentrated inactivated virus. If no viral cyto
pathic effect occurs after an incubation period of 7 days,

There is, however, no teaching in the art, or no example
in the scienti?c literature, that an inactivated viral vac

cine will protect mares against abortigenic infection by

equine rhinopneumonitis herpesvirus.

The present invention provides an injectable vaccina 40 each inoculated culture is harvested and transferred to a
tion program, timed to coincide with the most suscepti
second set of two cell cultures. If no viral cytopathic
ble period of gestation of the equine fetus, as well as an
effect occurs in these cultures after 7 days of incubation
immunogenically potent vaccine for immunizing horses
the virus is judged to be non-infectious.

against equine viral rhinopneumonitis and a process for
preparing the vaccine wherein an antigenically typical

(b) A virus pellet from the concentrated inactivated
virus base pool is examined by ultra thin section elec
tron microscopy to determine whether the inactivated
virus particles are enveloped. Because potency of vac
cine requires enveloped virions, the majority of the

and virulent equine rhinopneumonitis virus, propagated
in a physiologically homogeneous cell culture derived
as the recent progeny of a single cell cloned from a cell

culture derived from the skin of a normal equine fetus,

is chemically inactivated, concentrated by ultra?ltra

virions must be so constituted.
50

The inactivated virus must meet the following crite

tion and mixed for enhancement of immunogenic po
tency for injection with an oil based immunological

ria for immunogenic potency:

adjuvant.

decrease, in serial fashion, the number of inactivated

More particularly, the invention provides an intra
muscular vaccination protocol for protection of preg
nant mares against abortion caused by equine rhinop

The vaccine virus without adjuvant is diluted so as to

virions in the suspension. The dilutions are extended to
55

produce complete extinction of protective effect. A
portion of each diluted virus suspension is mixed and
emulsi?ed with an equal amount of oil based adjuvant.

neumonitis viral infection which consists in vaccinating
pregnant mares by injection in the 5th month of preg
nancy, in the 7th month and in the 9th month of preg
nancy, and of immunizing non-pregnant yearlings by a
series of two injections in September and an annual

vanted virus dilution. At the same time, four hamsters
are mock vaccinated using a 0.2 ml intramuscular injec

single injection vaccination until such female yearlings

tion composed of equal amounts of emulsi?ed diluent

Four Syrian hamsters (Cricetus auratus) are injected
intramuscularly with 0.2 ml of each dilution of adju

reach breeding age and become pregnant with a vaccine

and adjuvant. Three weeks later, the hamsters are all

prepared by:

challenged by intraperitoneal injection of at least 1

(A) Preparing from the dermis of a normal equine 65 million hamster median lethal doses of hamster virulent
fetus, removed aseptically from a pregnant normal
virus. The hamsters are individually housed for the
mare, a cell culture which by karyotypic analysis is
purposes of the test and are observed for 7 days follow
shown to be a diploid male or female idiogram without
ing challenge inoculation. The vaccine must protect

4,083,958
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hamsters vaccinated with a 1:1500 dilution of the base

L-glutamine, non-essential amino acids, 0.6 grams per

vaccine virus suspension. The mock vaccinated ham

liter vof bicarbonate, and 10 percent calf serum or fetal
calf serum. Virus growth curves illustrate conditions of

sters must all die within 7 days, and a titration of the
challenge virus in unvaccinated or mock vaccinated

incubation yielding maximum yields. Studies of virus
propagation determined that virus release into calf
serum-free medium is accomplished by removing

hamsters must show that the challenge virus contained
at least 1 million hamster median lethal doses. The po
tency titration endpoint is the dilution of adjuvanted

serum-containing medium before virus release occurs,

vaccine which protects 50 percent of vaccinated ham

thereby obtaining virus yields free of foreign serum

sters.

protein and hence removing extraneous antigenic mate
rial from the vaccine.
Infectious virus yields from cultures so prepared av
erage 6.0 to 7.0 X 106 plaque forming units per milliliter
of cell free virion‘s.
The virus suspensions harvested from such cell cul

The invention further provides a process for manu
facture of a vaccine characterized by the aforemen
tioned'protocols and the vaccine itself as a method for

protecting horses against disease caused by the equine
rhinopneumonitis virus.
As the virus, antigenically typical equine rhinop

tures are centrifuged to remove extraneous cell debris

neumonitis virus, the A-l83 strain, is used. The A-l83

and the supernatant solutions are pooled to constitute a

strain is immunogenically the same as strains of equine

production lot. The virus is chemically inactivated, the
residual inactivating chemical is neutralized and the

rhinopneumonitis virus recovered from diseased horses
in several countries of the world, speci?cally Germany,

Sweden, Switzerland, France, Great Britain, Ireland,
Japan, Australia, South Africa, Argentina, Brazil and
the United States. The virus may be recovered by inoc

virus is tested for inactivation by the test described
20

above. The inactivated virus pool is then concentrated
to increase antigenic potency by ultra?ltration using a
membrane with an exclusion limit of molecular weight

5000. A sample of the concentrated vaccine is pelleted
ulation of susceptible cell cultures, from the nasophar
by centrifugation and the virus pellet is examined by
ynx and/or blood of horses with respiratory disease,
from the nasopharynx and/or blood of infected preg 25 thin layer electron microscopy to determine the pres
nant mares and from the organs of fetuses aborted by
infected mares.

,

Although the virus may be cultured by multiplication
in cell cultures derived from organs of many mamma

ence of enveloped virions. The vaccine virus is tested
for bacterial contamination. A stabilizer and a preserva
tive such as thiomerosal are added.

The inactivated vaccine virus is emulsi?ed with an

lian species, for the purposes of this invention, the virus 30 equal amount of oil based adjuvant and dispensed asep
tically into suitable containers.
is cultured from the lung tissue of an infected aborted
The following example illustrates the invention but is
fetus by inoculation of a cloned, diploid cell culture
not intended to limit it thereto:
prepared from a cell culture derived from the dermis of
a normal equine fetus.
EXAMPLE I
The parent cell line is derived from the normal der 35
mal and subcutaneous connective tissues of a normal 10
to ll-month-old equine fetus. Monolayer cultures are

Of a group of 21 pregnant mares, 11 were vaccinated

the early subculture generations by single cell isolation
techniques. The growth characteristics of cloned cell

noted for each mare. Sixty days after vaccination the vaccinated mares and the 10 unvaccinated mares were

with adjuvanted, inactivated virus vaccine with a ham
ster irnmunogenic potency of 1:1600. There was no
prepared from the excised and trypsin dispersed fetal
untoward local or generalized reaction to injection of
connective tissue; cells from early 5th to 7th passage are
stored at —90° Centigrade. To obtain a physiologically 40 the vaccine. An immune response evident by post-vac
cinal increase in antibody and by other parameters ap
homogeneous cell population in culture as the progeny
plicable to in-vitro measurement of such response was
of a single cell, cloned lines of cells are initiated from

lines are determined by such techniques as plaquing 45 exposed to virulent rhinopneumonitis virus by the intra

efficiency, generation time and cell viability.
Karyotypic analysis of vinblastine treated cloned cell

nasal route which is the natural route of transmission of
the virus. Six of the unvaccinated mares aborted

rhinopenumonitis virus infected fetuses, four delivered
lines at the passage level selected for production of
normal foals. All of the vaccinated mares delivered
vaccine virus reveal diploid male or female idiograms
without demonstrable chromosome markers. The cell 50 normal foals.
The invention being thus described, it will be obvious
lines are shown to be free of mycoplasma and adventi
that the same may be varied in many ways. Such varia
tious viruses. Such cell lines have been shown to be

capable of propagating all strains of equine rhinop
neumonitis virus, equine cytomegalovirus, equine coital
exanthema virus, Herpes simplex virus, infectious bo
vine rhinotracheitis virus, Venezuelan equine encepha
lomyelitis virus, equine adenovirus, and equine arteritis
virus. The cell lines can be shown to be free of equine

infectious anemia virus by inoculation of susceptible
horses.
When rabbits are immunized with the cell lines, they

produce no antibodies reactive against known equine
red blood cell antigens. Inoculation of normal horses
with the cell lines produces no adverse effect.
For virus vaccine production, cell cultures are pre

pared as con?uent monolayers in glass or plastic roller
bottles. The cells are grown in medium consisting of

Eagle’s Minimal Essential Ingredient with Hank's salts,

tions are not to be regarded as a departure from the

spirit and scope of the invention, and all such modi?ca
tions are intended to be included within the scope of the

following claims.
What is claimed is:

~

1. A vaccination method against disease caused by
equine rhinopneumonitis virus in horses which com
prises (a) vaccinating young female horses at any age
past the time they reach their sixth month of age and
revaccinating them at appropriate intervals until the
females reach breeding age and become pregnant and
(b) vaccinating the pregnant mares during their preg
65 nancy and during subsequent pregnancies with an adju
vanted, inactivated vaccine prepared by: '

propagating a virulent, immunogenically typical
equine rhinopneumonitis virus in a susceptible,

5
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high yields of infectious virions;
harvesting the virus in a serum free medium;

be released into a serum-free medium;

completely inactivating the virions, neutralizing the

harvesting virus from the cell culture, inactivating
the virus, neutralizing the inactivating agent, con
centrating the virus and adding an oil based immu

inactivating agent, concentrating the virions by a
method that maintains structural integrity and in
creases antigenic potency; and
mixing the concentrated, inactivated virions with an

nological adjuvant thereto.
2. The vaccination method in accordance with claim

oil based immunological adjuvant,

1, wherein said harvested material meets the following
l0
criteria for safety and potency:

said harvested and adjuvant mixed material meeting
the following criteria for safety and potency;

(a) the virus is shown to be inactivated and non-infec

tive by its lack of ability to infect susceptible cell
cultures, and
(b) the vaccine is shown to be immunogenically po
tent by protection of hamsters against one million
hamster median lethal doses of hamster virulent

6
‘loid cell line and multiplying the virus to obtain

cloned, diploid equine cell line that contains no
equine blood cell antigens, and causing the virus to

(a) the virus is shown to be inactivated and non-infec
tive by its lack of ability to infect susceptible cell

cultures, and
(b) the vaccine is shown to be immunogenically po
tent by protection of hamsters against one million
hamster median lethal doses of hamster virulent

15

rhinopneumonitis virus.

rhinopneumonitis virus.

3. The vaccination method in accordance with claim
6. A vaccine for protection of horses against equine
1, wherein the young horses are revaccinated about 3 20 rhinopneumonitis prepared by the method of claim 5.
weeks after their ?rst vaccination and then at yearly
7. The method of protecting horses against equine

intervals thereafter until they reach breeding age.
4. The vaccination method in accordance with claim

horses with a vaccine prepared by the method of claim

3, wherein the pregnant mares are vaccinated at the

5.

rhinopneumonitis which comprises vaccinating said

?fth, seventh and ninth months of pregnancy.
8. The vaccination method in accordance with claim
25
5. The method of preparing a vaccine for parenteral
1, wherein said rhinopneumonitis virus is obtained from
vaccination of horses against disease caused by equine
an infected fetus.
rhinopneumonitis virus which comprises:
9. The method of claim 5, wherein said rhinop

propagating a virulent, immunogenically typical
equine rhinopneumonitis virus in a susceptible

neumonitis virus is obtained from an infected equine
30

equine, cloned, physiologically homogeneous, dip

fetal lung.
#
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